← FDA Drug Approvals (Drugs@FDA)

OXALIPLATIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: HETERO LABS LTD VI · Approved 2025-01-27

Drug application

FDA Application #

ANDA217925

Application type

Abbreviated New Drug Application (Generic)

Brand name

OXALIPLATIN

Generic name

OXALIPLATIN

Active ingredients

OXALIPLATIN

Dosage form

INJECTABLE

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

HETERO LABS LTD VI

Manufacturer

Camber Pharmaceuticals, Inc.

First approval

2025-01-27

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown